Drug Profile
R TPR 022
Alternative Names: R-TPR-022Latest Information Update: 15 Jul 2020
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 02 Jan 2018 Reliance Life Sciences plans a phase III trial for Asthma in India (CTRI2017-10-010093)
- 13 Oct 2017 Phase III trials in Asthma in India prior to October 2017 (SC) (CTRI2017-10-010093)